Ammon News - A committee tasked with reviewing drug prices in local market will meet on Sunday to discuss reducing the price of a new drug package over the next two months.

The Jordan Food and Drug Administration (JFDA) Director General Nizar Mheidat said that he asked the committee not to consider the prices of medicines under JD10 and to focus on higher-priced medicines.

Mheidat explained that medicines are subject to periodic re-pricing and re-registration, indicating that the prices of 848 pharmaceutical items will be reduced in 2022, 698 in 2023, and 626 in 2024, out of a total of 9,000 pharmaceutical items registered in Jordan.